While our findings and several prior studies support an oncogenic role for DDB2, particularly in breast cancer 47, melanoma 48, endometrial 49, and ovarian cancer 50 where it promotes proliferation, survival, and resistance to chemotherapy, other reports describe tumor-suppressive functions of DDB2 in different settings. Here, DDB2 is linked to ovarian carcinoma.